Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Will Focus On Pipeline For Near-Term Growth, CEO Says

Executive Summary

Genentech's near-term growth will be based on its product pipeline rather than through acquisitions, CEO Arthur Levinson, PhD, told analysts during the company's fourth quarter earnings call Jan. 16

You may also be interested in...



Genentech/Xoma Xanelim BLA delay

Genentech/Xoma's Xanelim (efalizumab) BLA filing will be delayed beyond summer 2002, companies announce April 5. A pharmacokinetic study comparing Genentech-produced to Xoma-produced drug did not achieve statistical definition of comparability. Genentech had projected a summer 2002 BLA filing for the psoriasis therapy (1"The Pink Sheet" Jan. 21, p. 32)...

Genentech/Xoma Xanelim BLA delay

Genentech/Xoma's Xanelim (efalizumab) BLA filing will be delayed beyond summer 2002, companies announce April 5. A pharmacokinetic study comparing Genentech-produced to Xoma-produced drug did not achieve statistical definition of comparability. Genentech had projected a summer 2002 BLA filing for the psoriasis therapy (1"The Pink Sheet" Jan. 21, p. 32)...

Herceptin Label Should Add Abbott/Vysis’ PathVysion HER2 Assay – Cmte.

Genentech's Herceptin (trastuzumab) labeling should add information about use of Vysis' PathVysion fluorescence in situ hybridization (FISH) test as an aid in selecting patients for therapy with the breast cancer drug, FDA's Oncologic Drugs Advisory Committee concluded Dec. 5

Related Content

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel